[go: up one dir, main page]

WO2010111374A2 - Compositions et procédés pour soulager des affections cutanées - Google Patents

Compositions et procédés pour soulager des affections cutanées Download PDF

Info

Publication number
WO2010111374A2
WO2010111374A2 PCT/US2010/028482 US2010028482W WO2010111374A2 WO 2010111374 A2 WO2010111374 A2 WO 2010111374A2 US 2010028482 W US2010028482 W US 2010028482W WO 2010111374 A2 WO2010111374 A2 WO 2010111374A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
active ingredient
group
chemicals
disorder
Prior art date
Application number
PCT/US2010/028482
Other languages
English (en)
Other versions
WO2010111374A9 (fr
Inventor
Betty Bellman
Original Assignee
Betty Bellman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betty Bellman filed Critical Betty Bellman
Publication of WO2010111374A2 publication Critical patent/WO2010111374A2/fr
Publication of WO2010111374A9 publication Critical patent/WO2010111374A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the disclosure relates generally to the field of skin care and alleviation of skin disorders.
  • Numerous skin disorders are known in the art, including atopic dermatitis, eczema, and dry skin, for example. Such disorders include those associated with dryness, loss of suppleness, itching, redness, cracking, flaking, and other common symptoms.
  • the invention relates to a method of alleviating a skin disorder in a person.
  • the method comprises applying fractionated coconut oil to at least a portion of the skin affected by the disorder.
  • the composition containing the fractionated coconut oil preferably includes no other skin-active agents, other than (optionally) one or both of a cromolyn compound and a corticosteroid.
  • Other skin-active ingredients can nonetheless be included.
  • the invention also relates to a method of inhibiting development of a skin disorder in a portion of the skin of a person. This method comprises applying fractionated coconut oil to the portion in an amount sufficient to inhibit development of the disorder.
  • the composition containing the fractionated coconut oil preferably includes no other skin-active agents, other than (optionally) one or both of a cromolyn compound and a corticosteroid.
  • the disclosure relates to compositions and methods for alleviating skin disorders.
  • a skin disorder including atopic dermatitis, eczema, and dry skin, for example
  • application of fractionated coconut oil can prevent or inhibit the onset or severity of a skin disorder.
  • coconut oil is an oil extracted from the flesh of coconuts (e.g., coconuts of the species Cocos nucifera). It is a fat consisting of about 90% saturated fat. The oil contains mostly medium chain triglycerides, with about 87% saturated fatty acids, 6% monounsaturated fatty acids, and 2% polyunsaturated fatty acids. Coconut oil is known to contain several different saturated fatty acids. Nonetheless, about 45% of the saturated fatty acids are lauric acid, about 17% are myristic acid, and about 8% are palmitic acid. Monounsaturated fatty acids in coconut oil include primarily oleic acid, and the only polyunsaturated fatty acid generally present is linoleic acid.
  • Fractionated coconut oil is a fraction of the whole oil, in which most of the long- chain triglycerides are removed, leaving only saturated fats in the fractionated oil.
  • Fractionated coconut oil is sometimes referred to as "caprylic/capric triglyceride” or MCT oil because mostly the medium-chain triglycerides (caprylic and capric acid) are left in the oil.
  • FCO tends to lack the scent normally associated with coconut oil (or, more properly, with the portions of coconut oil not present in FCO). FCO has a very light and clean skin feel, applies smoothly, and tends to dry more quickly than other known skin oils.
  • a person afflicted with a skin disorder applies FCO to their skin, or to the portions of the skin affected by the disorder.
  • the amount of FCO is not critical, and can be about as much oil as will ordinarily adhere to the skin at room temperature. Because FCO is not believed to exhibit any significant toxicity, it can be applied to the skin liberally, generally as often as desired by the person. In general, the FCO should be applied to the skin not less frequently than about once every few days, and not more frequently than every two hours, and preferably once or twice per day. This higher frequency is not dictated by safety or operability. Nonetheless, it is recognized that, at high application frequencies, the efficacy of the composition may be little or no greater than at lower application frequencies.
  • FCO can be applied to the skin of a healthy person (i.e., a person who is not afflicted with a skin disorder, or who is not recognized as being afflicted with a skin disorder) in order to prevent or delay the onset of the skin disorder, or to reduce the severity of the skin disorder should it occur.
  • the amount of FCO applied to the skin should be an amount sufficient to create a film of the oil on the skin, and not more than the amount that will adhere to the skin without dripping. This amount is believed to be approximately 5 milliliters per square meter of skin surface, although this amount is merely an estimate. Approximately 0.5 milliliters of FCO is sufficient to apply to front half of the thigh of an adult woman, for example.
  • the form in which the FCO is applied is not critical. Generally, because FCO is a liquid at room temperature, it can be applied as a fluid. By way of example, the FCO can be applied using a spray device or atomizer, by pouring or rubbing it onto the skin, by daubing it onto the skin using a sponge or brush, by rolling it on using a 'ball point pen' or 'roll-on deodorant' type container, or otherwise. Although the FCO is preferably applied as a liquid, it can be incorporated into a variety of bases or vehicles, such as creams, lotions, mousses, foams, pastes, or the like.
  • FCO can be applied as a solid, for example by rubbing or wiping the solid FCO onto the skin.
  • Specific examples of skin disorders that can be alleviated or prevented by topical application of FCO to the skin include atopic dermatitis, eczema, and dry skin. This list of disorders is not limiting. Other skin disorders can be similarly treated.
  • Patients of the applicant who have been afflicted with skin disorders and to whose skin FCO was applied as a spray patients were instructed to apply FCO at least once per day to affected areas and told that it could be applied more frequently if desired reported relief from their symptoms and general satisfaction with the skin characteristics obtained upon using the product.
  • One or more cromolyn compounds can be added to the composition to enhance its effectiveness and to alleviate additional symptoms.
  • Cromolyn compounds are known mast cell stabilizing agents that can prevent release of histamine from mast cells.
  • the composition can have the effects described herein for FCO and can also alleviate or prevent inflammation, itching, and irritation and decrease the severity of the same.
  • a cromolyn compound such as cromolyn sodium can, for example, be included in an amount of about 1% to about 10% by weight. Greater or lesser amounts can be added.
  • corticosteroids e.g., hydrocortisone
  • cromolyn compounds can be added to the composition, instead of or in addition to cromolyn compounds, in order to enhance the effectiveness of the composition and to alleviate additional symptoms.
  • corticosteroids are known in the art (e.g., hydrocortisone, desonide, alclometasone dipropionate, and methyl prednisone), and the identity of the corticosteroid added is not critical.
  • Corticosteroids can be added in effective amounts typically used in other topical compositions. For example, it is known to include hydrocortisone in amounts up to 1% (e.g. 0.1% - 1%) in topical consumer products sold without a prescription and in amounts greater than 1% in products available in the U.S. by prescription only.
  • the form in which the corticosteroid is added to the composition is similarly immaterial.
  • Suitable compositions can include corticosteroid incorporated in powdered form or in an aqueous solution (e.g., the composition can be a water-in-oil, oil-in-water, or other emulsion), for example.
  • FCO and skin-active ingredients include the following:
  • FCO FCO and one or more sunscreen chemicals such as mexoryl , oxybenzone, octisalate, titanium dioxide and zinc oxide.
  • sunscreen chemicals such as mexoryl , oxybenzone, octisalate, titanium dioxide and zinc oxide.
  • FCO and one or more anti-oxidants for skin rejuvenation such as vitamin C, green tea, coffee berry extract, vitamin E and idebenone.
  • FCO FCO and one or more anti-itch chemicals such as diphenhydramine, pramoxine, menthol and camphor.
  • FCO FCO and one or more anti-histamine substances such as olopatadine.
  • FCO FCO and one or more other constituents (i.e., ingredients) such as tar (e.g., coal tar), ketoconazole, zinc pyrithione, tea tree oil and sulfacetamide.
  • tar e.g., coal tar
  • ketoconazole e.g., ketoconazole
  • zinc pyrithione e.g., zinc pyrithione
  • tea tree oil e.g., tea tree oil
  • sulfacetamide e.g., sulfacetamide
  • FCO FCO and one or more anti-scabies chemicals such as permethrin, crotamiton, and ivermectin.
  • FCO and one or more anti-keratosis pilaris chemicals such as urea, lactic acid, and retinoic acid.
  • FCO and one or more anti-hyperkeratosis drugs such as salicylic acid for scaly heels, elbows and feet.
  • FCO FCO and one or more compounds such as propolis for lips, skin, and/or cold sores.
  • FCO FCO and one or more anti-fungal agents for athlete's foot such as miconazole, clotrimazole, nystatin, terconazole, and the like.
  • FCO FCO and one or more compounds such as clobetesol diproprionate, triamcinolone acetonide, fluocinonide steroid formulations for moderate inflammatory skin diseases (with or without zinc).
  • compounds such as clobetesol diproprionate, triamcinolone acetonide, fluocinonide steroid formulations for moderate inflammatory skin diseases (with or without zinc).
  • FCO FCO and one or more anti-infective compounds. Since patients with atopic eczema are frequently colonized with bacteria such as staphylococcus aureus, it would be important to add one or more chemicals such as mupiricin, altabax, or triclosan, to decrease colonization and or infection of the skin. This is especially so with the emergence of methycilin-resistant Staphylococcus aureus.
  • FCO FCO and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and one or more organic skin-active agents. Since FCO is natural and

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne la découverte que l'huile de noix de coco fractionnée est efficace pour soulager des affections cutanées existantes lorsqu'on l'applique par voie topique sur la peau d'une personne atteinte d'une telle affection. L'invention concerne en outre la découverte que l'huile de noix de coco fractionnée peut être utilisée pour prévenir ou inhiber la survenue d'une affection cutanée ou réduire la gravité d'une affection cutanée lorsqu'on l'administre en prophylaxie sur la peau d'une personne. Divers principes actifs au plan cutané peuvent être inclus dans la composition, en plus de l'huile de noix de coco fractionnée.
PCT/US2010/028482 2009-03-26 2010-03-24 Compositions et procédés pour soulager des affections cutanées WO2010111374A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16365909P 2009-03-26 2009-03-26
US61/163,659 2009-03-26

Publications (2)

Publication Number Publication Date
WO2010111374A2 true WO2010111374A2 (fr) 2010-09-30
WO2010111374A9 WO2010111374A9 (fr) 2011-02-03

Family

ID=42781847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/028482 WO2010111374A2 (fr) 2009-03-26 2010-03-24 Compositions et procédés pour soulager des affections cutanées

Country Status (1)

Country Link
WO (1) WO2010111374A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11906507B2 (en) 2020-03-24 2024-02-20 The Procter & Gamble Company Methods for testing skin samples

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11906507B2 (en) 2020-03-24 2024-02-20 The Procter & Gamble Company Methods for testing skin samples

Also Published As

Publication number Publication date
WO2010111374A9 (fr) 2011-02-03

Similar Documents

Publication Publication Date Title
US11534470B2 (en) Topical treatments incorporating Cannabis sp. derived botanical drug product
US20190021961A1 (en) Water-in-oil emulsion
KR20060021326A (ko) 약학제, 하나 이상의 휘발성 실리콘 및 비휘발성 오일상을함유하는 분무형 조성물
EP1069886B1 (fr) Usage d'une formulation de produit en application locale du type emulsion huile dans l'eau, comprenant comme emulsifiant un galactolipide, pour obtenir l'effet prolonge d'une substance incorporee
US20150328222A1 (en) Pain relief cream
US9011943B2 (en) Compositions and methods for alleviating skin disorders
CN101203277B (zh) 毛发滋补剂
US10238596B1 (en) Restorative formulations
US8383166B2 (en) Stable hydrophobic topical herbal formulationn
US20050063930A1 (en) Topical formulation of the oil-in-water type, comprising galactolipid material as emulsifier, with a prolonged effect of an incorporated active substance
US7488500B2 (en) Compositions and methods for alleviating skin disorders
CN106344589B (zh) 一种稳定性改善的卡泊三醇倍他米松组合物
US12144884B2 (en) Skin barrier protective delivery systems
US7758901B2 (en) Compositions and methods for alleviating skin disorders
Ruiz et al. Skin creams made with olive oil
WO2010111374A2 (fr) Compositions et procédés pour soulager des affections cutanées
EP3352724B1 (fr) Gel hydrophobe à base de vitamine e exempt de produits de silicone pour une application topique
JP7398589B1 (ja) ショウガ成分含有疼痛緩和用外用剤
KR20120058709A (ko) 안정화된 불포화지방산과 무방부제를 적용한 피부질환 개선용 외용제 조성물
US20220071922A1 (en) Delivery of health benefits through component formulation
WO2022031607A1 (fr) Compositions médicinales et méthodes de traitement associés
AU2023256610A1 (en) Skin barrier protective delivery systems and methods thereof
WO2008101239A1 (fr) Compositions et procédés d'apaisement de troubles de la peau
KR20070022754A (ko) 연고 및 2 개의 가용화 활성 성분을 포함하는 약학 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10756784

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10756784

Country of ref document: EP

Kind code of ref document: A2